10-Q: Hepion Pharmaceuticals Q1 2026 Financial Update

Hepion Pharmaceuticals reports Q1 2026 results with reduced operating expenses but continues to face going concern uncertainties, while also announcing a new diagnostic asset license.

Summary

• Hepion Pharmaceuticals filed its Form 10-Q for the quarterly period ended March 31, 2026.
• The company reported a net loss of $810,791 for the three months ended March 31, 2026, compared to a net loss of $6,105,887 for the same period in 2025.
• Total operating expenses decreased to $798,509 from $1,280,595 in the prior year's quarter, primarily due to lower general and administrative costs.
• Research and development expenses increased to $70,000 from $22,235, largely due to a new licensing agreement.
• As of March 31, 2026, the company had $2.6 million in cash and an accumulated deficit of $246.9 million.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year without additional capital.
• On February 25, 2026, Hepion licensed certain liver disease diagnostic assets from Cirna Diagnostics, LLC, accounting for it as an asset acquisition with $70,000 expensed.
• Subsequent to the quarter, on April 21, 2026, the company closed a private placement offering, raising $700,000 in gross proceeds.
• The company has no products approved for commercial sale in the U.S. but has three products with CE marks eligible for sale in the EU and other markets.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the persistent going concern issues, material control weaknesses, and lack of revenue, despite a reduction in net loss and a recent capital raise.

Positives

• Significant reduction in net loss for the quarter ($810,791 in Q1 2026 vs. $6,105,887 in Q1 2025).
• Total operating expenses decreased by approximately $482,086, driven by lower general and administrative costs.
• Secured a new intellectual property license agreement for liver disease diagnostic assets from Cirna Diagnostics, LLC.
• Completed a private placement offering subsequent to the quarter, raising $700,000 in gross proceeds.
• Three products have CE marks and are eligible for sale in the European Union and other eligible markets.

Negatives

• The company continues to have no revenue from operations.
• Substantial doubt exists regarding the company's ability to continue as a going concern within one year without additional capital.
• Accumulated deficit stands at $246.9 million as of March 31, 2026.
• The company has not generated revenue to date and has incurred substantial losses and negative cash flows since inception.
• Material weaknesses in internal control over financial reporting were identified, including insufficient personnel, lack of segregation of duties, and issues with the design and implementation of controls over complex accounting transactions and the income tax provision.

Risks

• The company's ability to raise substantial additional capital to continue as a going concern and fund planned operations in the near term.
• Uncertainties associated with obtaining and maintaining regulatory approval for product candidates.
• The rate and degree of market acceptance and clinical utility of product candidates.
• The success of collaborations and partnerships with third parties.
• The potential market opportunity for product candidates.
• The company's ability to compete with companies developing treatments for similar indications.
• The strength and enforceability of the company's intellectual property rights.
• The potential for significant dilution to stockholders if additional funds are raised by issuing equity securities.
• The possibility of restrictive covenants in debt financing impacting the ability to conduct business.
• The risk that management may need to curtail planned operations to conserve cash if sufficient additional capital cannot be raised.
• The potential for unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect the business.

Future Outlook

The company expects to continue to incur significant losses for the foreseeable future and requires additional financing to fund operations. The size of future net losses will depend on the rate of future expense growth and the ability to generate revenue. The company may need to curtail operations if additional capital is not raised. The company has three products with CE marks eligible for sale in the EU and other markets, but cannot guarantee when or how much revenue will be generated from them.

Management Comments

• We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control.
• We do not assume any obligation to update forward-looking statements as circumstances change and thus you should not unduly rely on these statements.
• We have not generated revenue to date and have incurred substantial losses and negative cash flows from operations since our inception.
• Our ability to continue operations after our current cash resources are exhausted depends on future events outside of our control, including our ability to obtain additional financing or to achieve profitable operations, as to which no assurances can be given.
• We cannot assure you that we will be successful in remediating the material weaknesses in a timely manner.

Industry Context

StockSavvy.ai notes that Hepion Pharmaceuticals operates in the highly competitive and capital-intensive biopharmaceutical sector, where success is heavily dependent on clinical trial outcomes, regulatory approvals, and securing ongoing funding. The shift towards diagnostic assets, as indicated by the Cirna Diagnostics license, suggests a strategic pivot or diversification. The company's ongoing struggle with 'going concern' status is a common challenge for early-stage biotechs, underscoring the critical importance of future financing and successful product development.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in various legal proceedings, but at this time, management has no reason to believe that the outcome will have a material adverse effect on its consolidated financial condition or results of operations.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to future equity issuances to fund operations. Continued uncertainty regarding the company's going concern status.
• Employees: Resignation of CEO may impact morale and operational continuity. New employment agreements for Executive Chairman and CEO indicate continued operational leadership.
• Creditors: The company's ability to meet its obligations is dependent on securing additional financing, which could impact creditors if not achieved.

Next Steps

• Continue research and development of current and future product candidates.
• Seek additional financing to fund operations and implement remedial actions for internal controls.
• Pursue commercialization of products with CE marks in eligible markets outside the U.S.
• Implement remediation plans for material weaknesses in internal control over financial reporting, contingent on raising additional capital.

Key Dates

Recommendation

Hepion Pharmaceuticals presents a high-risk, speculative investment profile. While the reduction in net loss and the licensing of diagnostic assets are positive developments, the persistent going concern issue, material weaknesses in internal controls, and lack of revenue generation are significant concerns. The recent capital raise provides a short-term reprieve but does not fundamentally alter the company's precarious financial position. A 'hold' recommendation reflects the need for further developments, such as successful clinical trial progression, significant revenue generation, or a clear path to resolving the going concern issue, before considering a more definitive investment stance.

Keywords

Hepion Pharmaceuticals, Form 10-Q, Quarterly Report, Financial Statements, Liver Disease, Diagnostic Assets, Cirna Diagnostics, Going Concern, Capital Raise, Research and Development, Clinical Trials, Regulatory Approval, Stockholders Equity, Accumulated Deficit